Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Elizaveta T WickDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.
Colton J TreadwayDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.
Zhijun LiDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA.
Nathan I NicelyDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.
Zhizhong RenDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA.
Albert S BaldwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hillgrid.10698.36, Chapel Hill, North Carolina, USA.
Yue XiongDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA.
Joseph S HarrisonDepartment of Chemistry, University of the Pacific, Stockton, California, USA.ORCID 0000-0002-2118-6524
Nicholas G BrownDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-6141-0164
University of North Carolina at Chapel Hill · USUniversity of the Pacific · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
The Physiological Function and Regulation of INK4 GenesR01CA068377 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARZLUFF, WILLIAM F. · 1995 to 2021
$6.5M
The ROC-Cullin Family of E3 Ubiquitin LigasesR01GM067113 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI XIONG, YUE · 2003 to 2019
$5.4M
Spindle Assembly Checkpoint SilencingR35GM128855 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nicholas Gene Brown · 2018 to 2026
$4.1M
P53 AND ATM CHECKPOINTS IN THYMIC LYMPHOMA SUPPRESSIONR01CA065773 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARZLUFF, WILLIAM F. · 1995 to 2010
$3.6M
Mechanisms of Metabolic Gene Mutations in CancerR01CA163834 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2012 to 2023
$3.1M
HIV-1 Vpr disrupts the IFN-TET-ISG pathway to promote HIV-1 infection and persistenceR01AI127346 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2016 to 2020
Viruses evolve mechanisms to exploit cellular pathways that increase viral fitness, e.g., enhance viral replication or evade the host cell immune response. The ubiquitin-proteosome system, a fundamental pathway-regulating protein fate in eukaryotes, is hijacked by all seven classes of viruses. Members of the Cullin-RING family of ubiquitin (Ub) ligases are frequently co-opted by divergent viruses because they can target a broad array of substrates by forming multisubunit assemblies comprised of a variety of adapters and substrate receptors. For example, the linker subunit DDB1 in the cullin 4-RING (CRL4)-DDB1 Ub ligase (CRL4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Insight into Viral Hijacking of CRL4 Ubiquitin Ligase through Structural Analysis of the pUL145-DDB1 Complex. · full record | Socratic